Advances in Biological Chemistry

Volume 4, Issue 2 (April 2014)

ISSN Print: 2162-2183   ISSN Online: 2162-2191

Google-based Impact Factor: 0.96  Citations  h5-index & Ranking

The Effect of Bergamot-Derived Polyphenolic Fraction on LDL Small Dense Particles and Non Alcoholic Fatty Liver Disease in Patients with Metabolic Syndrome

Full-Text HTML  XML Download Download as PDF (Size: 321KB)  PP. 129-137  

ABSTRACT

The occurrence of Metabolic Syndrome (MS) represents an independent risk factor for developing cardiovascular disease states in patients suffering from type 2 diabetes mellitus. Moreover, both the size of LDL particles and liver dysfunction identified as non alcoholic fatty liver disease (NAFLD) represent important biomarkers for the development of cardiometabolic risk in patients with MS. Here we studied the effect of bergamot polyphenolic fraction (BPF) in patients with MS and NAFLD. 107 patients were enrolled at the San Raffaele IRCCS (Rome). All of them showed ultrasonografic evidences of NAFLD and at least three out of five previous identified criteria for the diagnosis of MS. Patients were divided into two groups: one receiving placebo and the second receiving BPF 650 mg twice a day for 120 consecutive days. In the group receiving BPF 650 mg twice a day, a significant reduction of fasting plasma glucose, serum LDL cholesterol and triglycerides alongside with an increase of HDL cholesterol was found. This effect was accompanied by significant reduction of both ultrasonographic and metabolic biomarkers of NAFLD. Moreover, a significant reduction of small dense LDL particles, as detected via proton NMR Spectroscopy, was found after BPF treatment. In conclusion, our data confirm the beneficial effect of bergamot-extract in patients with MS an effect highlighted by significant reduction of small dense LDL particles and by improvement of NAFLD biomarkers. This suggests a potential preventive role of bergamot derivatives in reducing cardiometabolic risk.

Cite this paper

Gliozzi, M. , Carresi, C. , Musolino, V. , Palma, E. , Muscoli, C. , Vitale, C. , Gratteri, S. , Muscianisi, G. , Janda, E. , Muscoli, S. , Romeo, F. , Ragusa, S. , Mollace, R. , Walker, R. , Ehrlich, J. and Mollace, V. (2014) The Effect of Bergamot-Derived Polyphenolic Fraction on LDL Small Dense Particles and Non Alcoholic Fatty Liver Disease in Patients with Metabolic Syndrome. Advances in Biological Chemistry, 4, 129-137. doi: 10.4236/abc.2014.42017.

Cited by

[1] An update on the safety of nutraceuticals and effects on lipid parameters
2018
[2] The Role of Nutraceuticals in Statin Intolerant Patients
2018
[3] Anti-oxidant effect of bergamot polyphenolic fraction counteracts doxorubicin-induced cardiomyopathy: Role of autophagy and c-kitposCD45negCD31neg cardiac …
2018
[4] Metabolic outcomes of bergamot polyphenolic fraction administration in patients treated with second-generation antipsychotics: a pilot study
2017
[5] Low-Dose of Bergamot-Derived Polyphenolic Fraction (BPF) Did Not Improve Metabolic Parameters in Second Generation Antipsychotics-Treated Patients: …
2017
[6] Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
2017
[7] Nutraceuticals as an important part of combination therapy in dyslipidaemia
2017
[8] Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach
2017
[9] Low-dose of bergamot-derived polyphenolic fraction (BPF) did not improve metabolic parameters in second generation antipsychotics-treated patients …
2017
[10] Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: a 6 months …
2016
[11] Synergistic in vitro antioxidant activity and observational clinical trial of F105, a phytochemical formulation comprising Citrus bergamia, in subjects with moderate …
2016
[12] Essential oil components of orange peels and antimicrobial activity
2016
[13] Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study
Frontiers in Pharmacology, 2016
[14] Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: a 6 months …
2016
[15] The treatment of hyperuricemia
International journal of cardiology, 2015
[16] Studies on the protective role of Bergamot polyphenols in doxorubicin-induced cardiotoxicity
PharmaNutrition, 2015
[17] The effect of bergamot polyphenolic fraction in patients with non alcoholic liver steato-hepatitis and metabolic syndrome
PharmaNutrition, 2015
[18] The effect of bergamot on dyslipidemia
Phytomedicine, 2015
[19] Taking Back Control
2014
[20] Bergamot Polyphenols: Pleiotropic Players in the Treatment of Metabolic Syndrome
J Metabolic Syndome, 2014
[21] Matters of the Heart
2013

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.